Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Author

Jen Farmer

This email address is being protected from spambots. You need JavaScript enabled to view it.

Chief Executive Officer

Title Created Date Category
FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreich’s Ataxia Monday, August 14, 2017 Scientific News
Heart and Nervous System Pathology in Compound Heterozygous Friedreich Ataxia Thursday, August 10, 2017 Funded Research
Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich's ataxia Tuesday, August 8, 2017 Scientific News
Chondrial Announces FDA Orphan Drug Designation for CTI-1601, a Novel Investigational Technology for the Treatment of Friedreich's Ataxia Thursday, August 3, 2017 Scientific News
Pharmacological therapeutics in Friedreich Ataxia: The present state Friday, July 21, 2017 Funded Research
Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy model Friday, July 21, 2017 Funded Research
Call for Abstracts - 10th Annual Friedreich’s Ataxia Symposium Thursday, July 20, 2017 Scientific News
AFAF and FARA invite proposals for research projects that advance drug discovery, development of novel biomarkers or improve clinical outcomes in Friedreich’s ataxia patients Sunday, July 16, 2017 Funded Research
Circulating miR-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in Friedreich's ataxia patients Friday, July 14, 2017 Scientific News
How does performance of the Friedreich Ataxia Functional Composite compare to rating scales? Wednesday, July 12, 2017 Funded Research

SHARE

FacebookTwitterLinkedInYoutube
ra-philly-18.jpg
Site Map     Privacy Policy      Service Terms      Contact      Charity Navigator